| Literature DB >> 31100920 |
ThankGod E Onyiche1,2, Keisuke Suganuma3, Ikuo Igarashi4, Naoaki Yokoyama5, Xuenan Xuan6, Oriel Thekisoe7.
Abstract
Equine Piroplasmosis (EP) is a tick-borne disease caused by apicomplexan protozoan parasites, Babesia caballi and Theileria equi. The disease is responsible for serious economic losses to the equine industry. It principally affects donkeys, horses, mules, and zebra but DNA of the parasites has also been detected in dogs and camels raising doubt about their host specificity. The disease is endemic in tropical and temperate regions of the world where the competent tick vectors are prevalent. Infected equids remain carrier for life with T. equi infection, whilst, infection with B. caballi is cleared within a few years. This review focuses on all aspects of the disease from the historical overview, biology of the parasite, epidemiology of the disease (specifically highlighting other non-equine hosts, such as dogs and camels), vector, clinical manifestations, risk factors, immunology, genetic diversity, diagnosis, treatment, and prevention.Entities:
Keywords: Babesia caballi; Equine Piroplasmosis; Theileria equi; epidemiology; equines; tick-borne disease; ticks
Mesh:
Year: 2019 PMID: 31100920 PMCID: PMC6572709 DOI: 10.3390/ijerph16101736
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Worldwide distribution of regions where equine piroplasms have been detected or reported across different hosts in the last ten years (2008–2018).
Figure 2Photomicrograph of Giemsa stained blood smear in Equine Piroplasmosis (EP) parasites prepared from in vitro cultures. (A) Babesia caballi and (B) Theileria equi. The arrow on (A)indicates the two pear-shaped bodies of B. caballi joined at the posterior end; on (B) indicates the four shaped merozoites of T. equi referred to as the “maltese cross”.
Figure 3Schematic illustration of the life cycle of Theileria equi (A) and Babesia caballi (B) in the vertebrate host and invertebrate vector. Adopted from [23] with few modifications.
Figure 4Possible transmission routes of equine piroplasmosis.
Figure 5Schematic presentation of pathophysiology of anemia in equine piroplasmosis. The flowchart illustrates the sequence of events that culminates in anemia and other pathological sequellae.
Prevalence of equine piroplasmosis in horses in endemic continents and countries using different diagnostic methods (2008–2018).
| Diagnostic Technique | Year | Continent | Country | Sample Size | Prevalence (%) | Reference |
|---|---|---|---|---|---|---|
|
|
| Africa | South Africa | 129 | 0 and 3.0 | [ |
|
| Africa | Nigeria | 240 | 6.0 and 94.0 | [ | |
|
| Africa | Nigeria | 400 | 83.3 and 11.1 | [ | |
|
| Africa | Nigeria | 156 | 2.7 and 10.3 | [ | |
|
| Asia | Iran | 100 | 0 and 5.0 | [ | |
|
| Asia | Malaysia | 306 | 22.2 and 16.9 | [ | |
|
| Asia | Turkey | 27 | 0 and 4.8 | [ | |
|
|
| Africa | South Africa | 99 | 51.5 and 97.9 | [ |
|
| Africa | Egypt | 88 | 17.0 and 23.9 | [ | |
|
| Asia | United Arab Emirates | 105 | 10.5 and 33.3 | [ | |
|
| Asia | Saudi Arabia | 241 | 7.5 and 10.4 | [ | |
|
| Asia | Iran | 100 | 2.0 and 48.0 | [ | |
|
| Asia | Thailand | 63 | 11.1 and 3.2 | [ | |
|
| North America | Mexico | 248 | 27.4 and 45.2 | [ | |
|
| Europe | Switzerland | 689 | 1.5 and 4.4 | [ | |
|
| Europe | Netherlands | 300 | 3 and 1 | [ | |
|
| Europe | Hungry | 324 | NA and 31.8 | [ | |
|
| Europe | Spain | 3100 | 21.0 and 44.0 | [ | |
|
|
| Africa | Sudan | 131 | 0 and 25.2 | [ |
|
| Africa | South Africa | 99 | 0 and 12.1 | [ | |
|
| Africa | Tunisia | 104 | 0.9 and 11.5 | [ | |
|
| Africa | Egypt | 88 | 19.3 and 36.4 | [ | |
|
| Asia | Mongolia | 250 | 42.4 and 6.4 | [ | |
|
| Asia | Jordan | 288 | 7.3 and 18.8 | [ | |
|
| Asia | Korea | 224 | 0 and 0.9 | [ | |
|
| Asia | Thailand | 63 | 0 and 0 | [ | |
|
| Asia | Iran | 100 | 0 and 45.0 | [ | |
|
| Asia | India | 160 | 0 and 11.9 | [ | |
|
| Asia | Turkey | 125 | 0 and 8.8 | [ | |
|
| Asia | Indonesia | 235 | 2.1 and 6.4 | [ | |
|
| North America | Costa Rica | 130 | 20 and 46.2 | [ | |
|
| North America | Cuba | 100 | 25 and 73 | [ | |
|
| South America | Venezuela | 136 | 4.4 and 61.8 | [ | |
|
| South America | Brazil | 36 | 60 and 38.5 | [ | |
|
| Europe | Netherlands | 300 | NA and 1.6 | [ | |
|
| Europe | Hungry | 324 | NA and 15.1 | [ | |
|
| Europe | Romania | 178 | 2.2 and 20.3 | [ | |
|
| Europe | Italy | 263 | 10.3 and 70.3 | [ | |
|
|
| Africa | Sudan | 158 | 4.4 and 63.5 | [ |
|
| Africa | Egypt | 88 | 14.8 and 0 | [ | |
|
| Africa | Nigeria | 252 | 4.4 and 65.6 | [ | |
|
| Asia | United Arab Emirates | 105 | 15.2 and 32.5 | [ | |
|
| Asia | Korea | 184 | 0 and 1.1 | [ | |
|
| Asia | Jordan | 253 | 0 and 14.6 | [ | |
|
| Asia | Mongolia | 250 | 51.6 and 19.6 | [ | |
|
| Asia | China | 1990 | 51.2 and 11.5 | [ | |
|
| Asia | Thailand | 63 | 1.6 and 0 | [ | |
|
| Asia | Malaysia | 306 | 63.1 and 51.3 | [ | |
|
| Asia | India | 160 | 0 and 73.1 | [ | |
|
| Asia | Indonesia | 235 | 0.4 and 1.7 | [ | |
|
| South America | Brazil | 538 | 69.6 and 26.6 | [ | |
|
| South America | Venezuela | 694 | 23.2 and 14.0 | [ | |
|
| South America | Brazil | 39 | 7.7 and 43.5 | [ | |
|
| North America | Costa Rica | 130 | 69.2 and 88.5 | [ | |
|
| Europe | Greece | 524 | 1.1 and 9.2 | [ | |
|
| Europe | Italy | 673 | 8.9 and 39.8 | [ | |
|
| Europe | Spain | 108 | 6.5 and 53.7 | [ | |
|
|
| South America | Brazil | 582 | 54.6 and 28.5 | [ |
|
| Europe | France | 443 | 12.9 and 58.0 | [ |
Abbreviations: NA—not available in the text, CFT—Compliment Fixation Test, IFAT—Indirect Florescent Antibody Test, cELISA—Competitive Enzyme-linked Immunosorbent Assay, ELISA—Enzyme Linked Immunosorbent Assay, PCR—Polymerase Chain Reaction.
Prevalence of equine piroplasmosis in donkeys/mules in endemic continents and countries using different diagnostic methods (2008–2018).
| Diagnostic Technique | Year | Continent | Country | Equine Spec (Donkey/Mules) | Sample Size | Prevalence (%) | Reference |
|---|---|---|---|---|---|---|---|
|
| 2013 | Africa | Ethiopia | Donkeys | 393 | 1.8 and 12.2 | [ |
|
| 2015 | Africa | Kenya | Donkeys | 314 | 0 and 81.2 | [ |
| 2016 | Africa | Egypt | Donkeys | 51 | 0 and 18.0 | [ | |
|
| 2014 | Asia | Thailand | Mules | 177 | 3.4 and 7.3 | [ |
| 2016 | Asia | India | Donkeys | 20 | 0 and 80.0 | [ | |
| 2013 | Europe | Spain | Mules | 56 | 32.1 and 66.1 | [ | |
| 2013 | Europe | Spain | Donkeys | 53 | 17.0 and 47.2 | [ | |
| 2012 | South America | Brazil | Donkeys | 88 | NA and 73.9 | [ | |
|
| 2013 | Africa | Ethiopia | Donkeys | 395 | 13.2 and 55.7 | [ |
| 2016 | Africa | Egypt | Donkeys | 51 | 22.3 and 26.6 | [ | |
| 2014 | Asia | Thailand | Mules | 177 | 2.8 and 10.7 | [ | |
| 2015 | Europe | Italy | Donkey | 138 | 40.6 and 47.8 | [ | |
| 2012 | South America | Brazil | Donkeys | 88 | 93.2 and NA | [ | |
|
| 2016 | Africa | Egypt | Donkeys | 51 | 18 and 38.8 | [ |
| 2014 | Asia | Thailand | Mules | 177 | 0 and 1.7 | [ | |
| 2016 | Asia | India | Donkeys/mules | 20 | NA and 35.0 | [ | |
| 2012 | South America | Brazil | Donkeys | 88 | 20.5 and 31.8 | [ | |
| 2015 | Europe | Italy | Donkeys | 134 | 17.4 and 3.4 | [ |
Abbreviations: NA—not available in the text, CFT—Compliment Fixation Test, IFAT—Indirect Florescent Antibody Test, cELISA—Competitive Enzyme Linked Immunosorbent Assay, ELISA—Enzyme Linked Immunosorbent Assay, PCR—Polymerase Chain Reaction.
Reported prevalence on detection of DNA to Babesia caballi and Theileria equi in dogs and camels in endemic continents and countries using PCR.
| Year | Continent | Country | Species | Diagnostic Method | Sample Size | Prevalence (%) | Reference |
|---|---|---|---|---|---|---|---|
| 2003 | Europe | Spain, Portugal and France | Dogs | PCR | 10 | NA and 40.0 | [ |
| 2009 | Europe | Croatia | Dogs | PCR | 81 | 1.3 and 1.3 | [ |
| 2010 | Europe | France | Dogs | PCR | 166 | 0.6 and 19.0 | [ |
| 2019 | South America | Paraguay | Dogs | PCR | 284 | NA and 0.3 | [ |
| 2012 | Asia | Jordan | Camels | PCR | 100 | 60.0 and 40.0 | [ |
| 2015 | Asia | Iraq | Camels | PCR | 38 | 39.5 and 23.7 | [ |
Abbreviations: NA—not available in the text; PCR—Polymerase Chain Reaction.